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Blood flow modification by nicotinamide and metoclopramide in mouse
tumours growing in different sites
D.G. Hirst, B. Joiner & V.K. Hirst
CRC Gray Laboratory, PO Box 100, Mount Vernon Hospital, Northwood, Middx. HA6 2JR, UK.
Summary Nicotinamide (NA) and metoclopramide (MCA) have been shown to be sensitisers of the effects of
radiation and drugs in experimental rodent tumours growing in skin and muscle. We have used 86Rb uptake to
investigate the effects of these two drugs on the distribution of blood to a mouse carcinoma (NT) growing in
skin, muscle or the gut wall, as well as to the host normal tissue. NA caused an increase in cardiac output
distribution (COD) of between 17 and 92% to tumours in the three sites. When this increase is related to the
changes in COD to the host normal tissues, however, COD to tumours in skin and muscle was increased by a
factor of 1.8 and to tumours in the gut wall by a factor of 1.7. MCA caused a consistent increase in COD to
tumours growing in muscle, but the effects in tumours in skin and gut were variable with time. Again when
related to the change in COD to host normal tissues, a factor of 2.1 was seen for COD to tumours growing in
muscle and gut. Both NA and MCA alter COD to tumours in some sites relative to host tissues in a way that
could enhance anti-cancer drug delivery to tumours, though the effects of NA are more reliable in our systems.
The structurally similar compounds nicotinamide (NA) and
metoclopramide (MCA) have been investigated as adjuncts to
experimental radio and chemotherapy (Jonsson et al., 1985;
Horsman et al., 1986; Lybak et al., 1991). Both NA, the
amide derivative of vitamin B3, and MCA, a commonly used
anti-emetic drug (Gralla et al., 1981) have been shown to
sensitise rodent tumours to radiation (Jonsson et al., 1985;
Horsman et al., 1986; Lybak et al., 1990). It has been sug-
gested, based largely on studies with cells in culture that each
of these compounds can inhibit the effective repair of DNA
damage in irradiated mammalian cells (Ben Hur, 1983; Pero
et al., 1989). There is also ample evidence to show that NA
at high doses significantly increases blood flow to intradermal
mouse tumours (Horsman et al., 1988; Horsman et al.,
1989a). MCA has been shown to potentiate the cell killing
effects of radiation and cisplatin in a subcutaneous human
carcinoma xenograft in the mouse (Kjellen et al., 1989;
Lybak et al., 1990; Lybak et al., 1991), effects that the
authors attributed to the ability of MCA to damage DNA
directly and to inhibit the repair of damage caused by other
agents. No sensitisation of normal tissues was observed with
MCA after either radiation or cisplatin, whereas NA did
cause some sensitisation in normal tissues though less than in
tumours.
The purpose of the present study was to compare the
effects of NA and MCA on the perfusion of a mouse car-
cinoma growing in three different sites, one of which is
relevant to cancer of the large bowel. All previously pub-
lished studies on NA and MCA have been carried out in
superficial tumours growing in mouse skin or muscle. We
have chosen to compare effects in tumours in these two
conventional sites with deep seated tumours implanted in the
gut wall using a novel technique which is described for the
first time in this paper.
Materials and methods
Animals and tumour systems
The NT mammary carcinoma growing in its syngeneic host
the CBA mouse was used in all the experiments. Implanta-
tion of tumours in the three sites was carried out at intervals
such that, allowing for the differences in growth rate in each
site they reached approximately the same size (-400 mg) on
the day of the experiment. All mice were males weighing
28-32 g at 12-16 weeks of age. Intradermal (i.d.) tumours
were first implanted as a suspension of about 2 x IO0 cells
(obtained by disaggregation of i.d. tumours from donor
mice) in 0.05 ml saline under metofane anaesthesia, into the
dorsal skin about 2 cm from the base of the tail. Four days
later a 'patch' technique (see below) was used to initiate
tumours in the gut wall. After a further 3 days tumour cell
suspension was injected into the right gastrocnaemius muscle.
Tumourpatch technique
The principle of the tumour patch technique is to hold a
piece of tumour against the surface of the visceral organ of
interest long enough for its cells to begin invasion, while
preventing cells from being shed from the tumour surface
and seeding throughout the peritoneal cavity. Donor tumours
were obtained from animals with tumours growing intrader-
mally on the back. Tumours were excised and sliced into
1 mm cubes which were kept moist with saline. Millipore
filters (0.2 Am pore size) were formed into 6 mm diameter
discs using a hole punch.
Recipient mice were anaesthetised by metofane inhalation
and an incision made through the skin and body wall of the
abdomen above the position of the organ of interest. Ocular
retractors were used to hold open an aperture of about
1 cm2. One piece of tumour was placed in the centre of a
prepared filter disc and placed on the anterior surface of the
organ, in this case the caecum. Tissue adhesive (Histo-
acryl, Cyanamid, Gosport, Hants.) was applied to the
periphery of the disc, fixing it to the underlying organ. Thus,
peritoneal fluid could pass through the filter to provide nut-
rients to the tumour cube until it could establish a blood
supply, but tumour cells could not escape to initiate deposits
elsewhere. When the adhesive was dry (-1 min) the exposed
gut was returned to its original position and the muscle
incision closed with suture and the skin closed with clips.
It is, of course, impossible to obtain accurate measure-
ments of volume for tumours growing in internal organs.
Measurement of tumour volume at each time point after
implant therefore required a separate group of animals to be
used. Contrary to our expectations, however, growth rates
were very homogeneous for tumours in this site, possibly
reflecting the constancy of the temperature, and this allowed
relatively few animals to be used to obtain the mean growth
rates.
Measurement ofcardiac output distribution to organs
The 86Rb uptake method (Sapirstein, 1958) was used to
measure the relative cardiac output distribution (COD) to
vaious tissues. The isotope (0.185 MBq; specific activity
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37-300 MBqmg-') was obtained from Amersham Interna-
tional plc, Aylesbury, UK. It was injected i.v. in 0.1 ml of
saline into the mouse tails that had been prewarmed in water
to facilitate injection. The mice were killed 1 min later by
neck fracture and the relevant tissues excised. The weight of
all tissues was recorded and they were then placed in double
thickness tubes (glass and polystyrene) and counted in a
gamma counter (LKB Wallac 1282 Compugamma, Phar-
macia LKB Biotechnology, Milton Keynes). A standard of
0.1 ml of the injected solution was also counted in each
experiment. Results were expressed as the % of the injected
activity per gram of tissue. Animals were excluded from the
analysis ifmore than 10% of the injected activity remained at
the site of injection.
Administration ofdrugs
NA and MCA (both from Sigma Chemical Company Ltd,
Poole, Dorset) are highly water soluble and were admin-
istered i.p. in saline at doses of 1000 and 2 mg kg-' respec-
tively in a volume of 0.01 ml g-' body weight.
Results
Figure la-c shows the sequence of tumour growth in the gut
wall after implant by the 'patch' technique. For the first 3
days tumour cells remain adherent to the millipore filter and
spread out laterally, by 6 days tumours have become
attached to the gut wall, induced a vascular supply and
exhibited regions of viable tumour tissue and of necrosis;
thus we can deduce that invasion of the gut wall began
between day 3 and day 6 after implant. By 17 days the
tumour has grown to about 0.8 cm in diameter and is mor-
phologically similar to NT tumour implanted in the skin.
Even at the largest sizes we have allowed in our experiments
(-1.2 g) the mucosal layer remained a barrier to tumour
invasion, although the muscle layers were quickly breached.
Figure 2 shows NT tumour weight as a function of time after
implant into the gut wall. Growth was exponential over the
period from 10-20 days, but then there was no further
increase in weight from 20 to 25 days. These last 5 days
corresponded with the appearance ofmetastases and a loss of
body weight so tumours were always used in the experiments
during the exponential phase of growth.
........ i. <.. ........;.. ........ ......
.......
SliS6'RES......
bTUMOUR BLOOD FLOW AFTER NICOTINAMIDE AND METOCLOPRAMIDE 3
-c
0.
E
0
:.....1 ...........
:' .:: .e. .:~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.. ... x.,<....s | | ll |~ ~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~..
ta~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~... .:: ... :.*........
...
.a
Figure la-c The growth of NT carcinomas attached to the gut wall. The scale bars show 500 gm. a, Three days after implant
tumour cells (T) have spread along the inner surface of the millipore filter disc (F). There is no contact with the gut tissue and no
vascularisation of the tumour. b, By day 6 tumour has attached to and invaded the gut wall. c, By day 17 the tumour has grown to
about 0.6 g. There is extensive necrosis interspersed with cords of viable tumour around blood vessels. Tumour invasion of the gut wall has progressed though the mucosal layer has not been breached.
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at no individual time was the increase statistically significant.
The maximum change in COD to tumours and the effect on
the host normal tissues at that time is summarised in Table I.
Metoclopramide produced changes in COD to two of the
three tumour sites (Figure 4). It was significantly elevated at
6 h after MCA in the gut tumours, at 0.5, 1.5, 3 and 6 h in
the muscle tumours where a 130% increase was observed,
but at no time in the skin tumours was the increase
significant. The three host normal tissues, skin, muscle and
gut, did not respond consistently to MCA (Figure 4). The
only significant effects were a decrease in COD to muscle
5 min and 6 h after adminsitration.
30
Days after implant
Figure 2 Growth curves for the NT tumour growing in the gut
wall. Exponential growth is followed by an abrupt cessation of
tumour enlargement at about 1-1.2 g in weight. The volume
doubling time during exponential growth was 3.4 days. A
minimum of six tumours contributed to each data point. Error
bars are ± 1 s.e.
Changes in COD to several normal tissues and tumours in
different sites after i.p. administration of NA (1000 mg kg-')
and MCA (2 mg kg-') were studied. A minimum of 6 and
maximum of 15 separate determinations from two or three
separate experiments were combined for each time point.
Figure 3 compares the effect of NA in NT carcinomas grow-
ing in three different sites, intradermally on the back intra-
muscularly in the leg and in the gut wall. Uptake in the three
host normal tissues is also shown. COD to intradermal
tumours was increased by 30-43% over the period 0.5-1.5 h
after NA though only at 0.5 h was the effect statistically
significant (P<0.05). In gut wall tumours, however, there
was a highly significant (P<0.01) increase in COD by 90%;
no significant change in COD occurred in the intra-muscular
tumours. In the normal tissues, skin showed a reduced COD
by about 20% over the period 0.5-1.5 h and muscle showed
much more prolonged and highly significant (P<0.01)
reduction. By contrast, COD to the gut was increased though
to a much lesser extent than that seen in the gut tumours and
Discussion
The rate of growth of these NT carcinomas varied with
implantation site. We may speculate that this reflects
differences in the local environment, such as temperature,
nutrient availability and vascularisation. Our data do not
allow any detailed analysis of these factors, but a comparison
of growth rates for i.d. (data not shown) and gut tumours
(Figure 2) reveals mean volume doubling times over the
macroscopic size range of 4.3 and 3.4 days respectively, a
sufficient difference to account for the time to reach experi-
mental size. Thus, it is the growth rate during the period
when the tumour is dependent on a blood supply that is
important, suggesting a better blood supply to gut than skin.
While this is consistent with the COD data (Figures 3 and 4),
the normal gut receiving -9 x as much of the cardiac
output per gram as the skin, host organ blood flow cannot be
the only factor as muscle tumours grew fastest of all yet
muscle recieves only a third as much of the cardiac output as
gut.
The use of vasoactive drugs to modify the distribution of
blood flow between tumours and normal tissues has been
described in numerous publications (Chaplin et al., 1991;
Hirst, 1989; Jirtle, 1988). A wide variety of methods have
been used to determine perfusion and they give information
about changes in either absolute blood flow (ml/min/l00 g)
or cardiac output distribution (COD). The latter will be more
important when considering the exposure of tissues to
anticancer agents in the circulating blood. The Rb extraction
method gives this information; it also gives a volume4 D.G. HIRST et al.
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Figure 3 The effect of NA (1000 mg kg- ) on the distribution of the cardiac output, as measured by the uptake of 86Rb, to NT
carcinomas growing in three different sites in the mouse. Distribution to the three host normal tissues is also shown. Error bars are
± 1 s.e.; hatched area shows control range ( ± 1 s.e.).
averaged distribution for the whole tumour reducing the
influence of microregional heterogeneity. This may be an
advantage or a disadvantage depending on the questions
being asked. Further studies to look specifically at micro-
regional heterogeneity of blood flow using '25Iodo-antipyrine
autoradiography are in progress.
Nicotinamide is known to be an effective sensitiser of
tumours to radiation (Jonsson et al., 1985; Horsman et al.,
1986) and there is considerable evidence that regional blood
flow modification is responsible for at least part of this effect
through oxygenation of radioresistant hypoxic cells (Chaplin
et al., 1990; Horsman et al., 1988; Horsman et al., 1989a).
Rb extraction was one end point used in one of these studies
(Horsman et al., 1988) using the RIF-1 tumour growing in
the skin. The results obtained in the present study for the NT
carcinoma are summarised in Table I. There are several ways
that these data could be analysed, but we have chosen to
take the maximum increase in tumour COD for each drug
and site and relate that to the change in COD to the host
normal tissue at that time. In the skin tumours, there was a
transient increase in (COD) persisting for about 1.5 h, and
reaching a maximum of 140% of control at 0.5 h after NA.
The response in gut tumours was both larger (190% of
control at 2 h) and more prolonged (>4 h). The host normal
tissues were at least as responsive as the tumours in the same
site, though the effect was not in any way predictable. For
example COD was reduced in skin and muscle, but there was
a trend towards an increase in gut. This suggests that the
increase or decrease in COD to tumours is unlikely to be
simply the result of diversion of blood to or from the local
normal tissues.
More quantitatively what do these effects mean for tumour
therapy? In the case of skin, COD was reduced to about 80%
of control so that for this tumour/host tissue pair, tumour
exposure to blood borne agents would be increased by a
factor of 1.75 compared with the host tissue (see Table I).
This argument is made on the assumption that the agent has
a short plasma half life and its supply by the blood is the
limiting factor in delivery to tissues. The extent to which this
is not the case for a particular agent will reduce the redis-
tribution effect. It is of interest to note that in the situation
where the agent is largely retained at the first pass through
the tissue, such as occurs with microspheres alone or in
combination with chemotherapy drugs, the full 1.75 factor
Table I Changes in cardiac output distribution after NA and MCA
COD @ ACODmax COD @ (h) % con. (tumour)/
Site COD (con.) Tumour % control COD (con.) Normal tissue % control % con. (norm)
i.d. 0.77±0.07 1.10±0.11 @ 0.5h 143 1.12±0.57 0.91 ±0.08 @ 0.5h 81 1.75
NA i.m. 1.39±0.16 1.62 0.23 @ 4h 117 2.37±0.17 1.53±0.26 ( 4h 65 1.80
gut 0.89±0.16 1.71 0.16 @ 2h 192 9.13±0.79 10.18±0.72 @ 2h 112 1.71
i.d. 0.49±0.05 0.65±0.19 @ 3h 139 0.98±0.10 1.02±0.10 @ 3h 104 1.34
MCA i.m. 0.79±0.10 1.85±0.27 @ 3h 234 2.49±0.15 2.82±0.22 @ 3h 113 2.07
gut 0.93 0.09 1.48 0.11 @ 6h 159 8.93±0.75 6.69± 1.03 @ 6h 75 2.12
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Figure 4 The effect of MCA (2 mg kg-') on the distribution of the cardiac output, as measured by the uptake of 86Rb, to NT
carcinomas growing in three different sites in the mouse. Distribution to the three host normal tissues is also shown. Error bars are
± 1 s.e.; hatched area shows control range ( ± 1 s.e.).
should apply. Tumours growing in the gut wall showed a
maximum increase in COD to 192% of control at 2 h
whereas the host gut tissues showed an increase to only
112% at that time. It should be noted, however, that the
absolute COD to the gut remained many times higher than
that seen in the gut tumour. Thus, after NA, the increase in
COD favoured the tumour by a factor of 1.71 (Table I).
While there was no significant effect in muscle tumours, the
large reduction in normal muscle (to 65% of control) meant
that COD again favoured the tumour by a factor of 1.80.
Thus, the tumour to host normal tissue ratio of COD did not
differ greatly (1.7-1.8) between implantation sites.
Metoclopramide has been shown to be a sensitiser of
tumours to drugs and radiation (Lybak et al., 1990; Lybak et
al., 1991) and a mechanism of DNA repair inhibition has
been proposed, based on in vitro studies with human
mononuclear leucocytes (Lybak & Pero, 1991). The evidence
for this mechanism is convincing and yet so is the evidence
for repair inhibition in vitro by NA even though it has been
shown clearly that the predominant mechanism of tumour
radiosensitisation is by improved tumour perfusion (Hors-
man et al., 1989b; Chaplin et al., 1990). It was not therefore
surprising that MCA should show some vasoactive proper-
ties. All previous studies with MCA have been carried out in
tumours growing in the flank skin (Lybak et al., 1990; 1991).
Our data for intradermal tumours (Figure 4) showed no
significant increase in COD at any one time, though there
was a trend towards an early decrease and later increase in
COD. Radiosensitisation has been reported (Lybak et al.,
1990) when MCA at the same dose as used in the present
experiments was given 15 min before irradiation, so unless
the MCA caused a large increase in cardiac output or a
reduction in intermittent blood flow (Chaplin et al., 1990) to
tumour micro-regions without any overall change in per-
fusion, it seems unlikely that the radiosensitisation achieved
in that study could have resulted from increased blood flow
and oxygenation.
Apart from improved oxygenation could there be a role
for MCA to increase blood flow distribution to tumours
relative to host normal tissues? In skin tumours there was no
significant improvement suggesting that chemosensitising
effects of MCA (Kjellen et al., 1989) probably do not result
from increased blood flow distribution. A large differential
was, however, seen in tumours growing in muscle where
COD was significantly (P<0.05) elevated to about 230% of
control from 0.5-6 h after MCA whereas COD was not
significantly increased in normal muscle at any time and
showed a large decrease at 6 h. A statistically significant
(P<0.05) increase in COD to 159% of control to tumours
growing in the gut wall was seen only at 6 h after MCA, at a
time when perfusion of the normal gut was reduced, though
not significantly leading to a large shift in favour of tumour
perfusion by a factor of 2.12 (Table I). Thus, MCA shifted
the distribution of the cardiac output substantially in favour
of NT carcinomas over the host normal tissues in two of
three sites, an effect which could be exploited therapeutically.
NA and MCA were both capable of shifting COD in
favour of tumours, but while this was seen in all sites with
NA, it was only really convincing in muscle tumours with
MCA though the increase there was quite dramatic. Thus,
while the best approach to distributing more blood to
tumours than to normal tissues might lie in selecting a
specific agent for a particular growth site (e.g. MCA for
tumours in muscle), the safest approach at present must be
the use of NA as there is no evidence from our studies or any
others of the opposite effect being seen in any site.
This work is supported entirely by the Cancer Research Cam-
paign.
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